Geno Germano - Medicines Independent Director
Director
Mr. Geno J. Germano is Independent Director of the company. He was a director since November 2017. Since August 2018 Mr. Germano serves as the chief executive officer and president of Elucida Oncology, Inc. From June 2016 to March 2017, Mr. Germano served as president of Intrexon Corporationrationration, a leader in synthetic biology. He previously held the position of group president of the Global Innovative Pharma Business of Pfizer, Inc., where he led a growing global 14 billion business with marketleading medicines and an extensive portfolio of latestage development candidates. Mr. Germano was also cochair of Pfizers Portfolio Strategy and Investment Committee and, prior to that, president and general manager of Pfizers Specialty Care and Oncology business units. Prior to joining Pfizer, Mr. Germano held numerous executive and leadership roles at Wyeth Pharmaceuticals, including president of Wyeth U.S., where he was responsible for the delivery of operational results across four business units, as well as president of its Global Pharmaceutical and Womens Healthcare Business. Mr. Germano was a member of the Group of Fifty and served on the board of the Biotechnology Innovation Organization, where he was a member of the executive committee and chaired the International Committee. He serves on the advisory board of the Healthcare Businesswomens Association and was a trustee of the Albany College of Pharmacy from October 2008 to October 2017. Mr. Germano is currently a director of Sage Therapeutics, where he is also the chair of their nominating and governance committee, and was formerly a director of Zoetis Inc. and Bioverativ Inc. since 2017.
| Age | 57 |
| Tenure | 7 years |
| Phone | 973 290-6000 |
| Web | www.themedicinescompany.com |
Medicines Management Efficiency
Medicines' management efficiency ratios could be used to measure how well Medicines manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 865 M in liabilities. Medicines has a current ratio of 0.75, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Medicines until it has trouble settling it off, either with new capital or with free cash flow. So, Medicines' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medicines sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medicines to invest in growth at high rates of return. When we think about Medicines' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Chen Heng | Sea | N/A | |
| Pamela Carter | Sea | 65 | |
| Tao Zhang | Sea | N/A | |
| Jay Grossman | Nexstar Broadcasting Group | 58 | |
| Thomas McKane | LB Foster | 70 | |
| Dennis FitzSimons | Nexstar Broadcasting Group | 67 | |
| Miranda Hubbs | Sea | 48 | |
| Hou Tianyu | Sea | 46 | |
| Peter Hamilton | Sea | 68 | |
| Clarence Cazalot | Sea | 64 | |
| Tianyu Hou | Sea | 46 | |
| Joseph Alvarado | Sea | 62 | |
| Michael Phelps | Sea | 67 | |
| Diane Owen | LB Foster | 62 | |
| Thomas McMillen | Nexstar Broadcasting Group | 65 | |
| Bradley Vizi | LB Foster | 34 | |
| Lisbeth McNabb | Nexstar Broadcasting Group | 57 | |
| Martin Pompadur | Nexstar Broadcasting Group | 82 | |
| William Rackoff | LB Foster | 69 | |
| Jeffrey Rea | Verra Mobility Corp | 53 | |
| Austin Adams | Sea | 71 | |
Management Performance
| Return On Equity | -10970.3 | |||
| Return On Asset | -0.0017 |
Medicines Leadership Team
Elected by the shareholders, the Medicines' board of directors comprises two types of representatives: Medicines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medicines. The board's role is to monitor Medicines' management team and ensure that shareholders' interests are well served. Medicines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medicines' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Melvin Spigelman, Independent Director | ||
| Christopher Visioli, CFO, Treasurer | ||
| Armin Kessler, Independent Director | ||
| Fredric Eshelman, Non-Executive Chairman of the Board | ||
| Christopher Cox, Executive Vice President chief corporate development officer | ||
| Krishna Gorti, IR Contact Officer | ||
| Geno Germano, Independent Director | ||
| Stephen Rodin, Senior Vice President General Counsel, Secretary | ||
| William Crouse, Independent Director | ||
| Robert Savage, Independent Director | ||
| Stuart Kingsley, President COO | ||
| Alexander Denner, Director | ||
| Robert Hugin, Independent Director | ||
| John Kelly, Independent Director | ||
| Elizabeth Wyatt, Lead Independent Director | ||
| Hiroaki Shigeta, Independent Director | ||
| Mark Timney, CEO, Director | ||
| Tony Kingsley, President COO | ||
| Sarah Schlesinger, Independent Director | ||
| Clive Meanwell, Chairman of the Board, CEO | ||
| Jeffrey Frazier, Executive Vice President Chief Human Strategy Officer | ||
| Paris Panayiotopoulos, Director | ||
| William OConnor, CFO |
Medicines Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medicines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10970.3 | |||
| Return On Asset | -0.0017 | |||
| Profit Margin | (0.0001) % | |||
| Operating Margin | (58.54) % | |||
| Current Valuation | 7.33 B | |||
| Shares Outstanding | 79.93 M | |||
| Shares Owned By Insiders | 4.22 % | |||
| Shares Owned By Institutions | 95.78 % | |||
| Number Of Shares Shorted | 25.18 M | |||
| Price To Earning | (3.24) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Medicines in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Medicines' short interest history, or implied volatility extrapolated from Medicines options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Medicines information on this page should be used as a complementary analysis to other Medicines' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Medicines Stock
If you are still planning to invest in Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medicines' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |